Immunai
PrivateLast Round
Series C
Oct 29, 2024
Est. Valuation
$1B
Total Funding Raised
$295M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Immunai operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Series C round in October 2024.
Immunai is a biotechnology company that leverages artificial intelligence and single-cell genomics to map the immune system for the development of targeted immunomodulatory therapeutics.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service, Revenue Share
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immunai Comparables
Compare Immunai with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Insitro | 88% | |
| Owkin | 83% | |
| Recursion Pharmaceuticals | 83% |
For institutional investors. Book with your work email.
Immunai Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 29, 2024 | ||||
| Series B | Oct 27, 2021 | ||||
| Series A | Feb 11, 2021 | ||||
| Seed | May 14, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Immunai Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ICON | Series B |
| Duquesne Family Office | Series A |
| Koch-ventures.com | Series B |
| Gefen Capital | Series B, Series A |
| Charles and Lynn Schusterman Family Philanthropies | Series A |
| Schusterman Family Investments | Series A |
| Catalio Capital Management | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 39% MoM.
- Jan 15, 2026
Partnered with Bristol Myers Squibb on a strategic collaboration.
For institutional investors. Book with your work email.
Immunai Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Immunai's valuation, stock price, and market status.
Is Immunai a public or private company?
Immunai is a private company.
What is the current stock price of Immunai?
Immunai is a private company, so its shares have no public market price. Caplight tracks Immunai's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Immunai worth (valuation)?
Immunai's valuation is estimated at $1.0B based on funding round data.
Can I buy Immunai stock?
Immunai shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Immunai's last funding round?
Immunai's most recent funding round was Series C on October 29, 2024.
Who are the main investors in Immunai?
Key investors in Immunai include Duquesne Family Office, Koch-ventures.com, Schusterman Family Investments, Catalio Capital Management, TLV Partners.
Will Immunai IPO soon?
No public IPO plans have been announced for Immunai.
How can I track Immunai secondary market activity?
Caplight tracks bids, offers, and trades in Immunai's shares on secondary markets.